Organon & Co.
NYSE:OGNDrug Manufacturers - General
+$0.01 today
- Market cap
- $3.66B
- Beta
- 1.54
- P/E (TTM)
- 14.2
- EPS (TTM)
- $0.94
- Dividend yield
- 0.60%
Volume 3.90M
Average 8.57M
OGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Organon & Co.NYSE: OGN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development declines year over year
Q3 FY2026 research & development of $83M fell 1.2% year over year, ahead of the -11.9% change in trailing-twelve-month research & development. Sequentially, it fell 7.8% from the prior quarter. Over 3 fiscal years it compounded at -8.1% a year.
Context
- Research & development amounted to 5.9% of revenue in FY2025, down 1.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -1.2% holds above the trailing-twelve-month pace of -11.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 366M USD
- Year-over-year change
- -22.0%
- 4-year CAGR
- -4.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 366M | -22.0% |
| FY2024 | 2024-12-31 | 469M | -11.2% |
| FY2023 | 2023-12-31 | 528M | +12.1% |
| FY2022 | 2022-12-31 | 471M | +6.3% |
| FY2021 | 2021-12-31 | 443M | — |
Research & Development vs competitors
How OGN compares with its peers on the latest reported figures
- OGN's LTM Sep 2026 research & development of $357M is the highest of the 10 companies compared; the peer median is $296.57K.
- Its year-over-year change of -11.9% is the 5th highest of 6, against a peer median of +18.2%.
- Research & development amounts to 5.9% of revenue for OGN, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $357M | -11.9% | -8.1% | 5.9% | |
| LTM Jun 2026 | $220.87M | +52.6% | +38.8% | 23.0% | |
| LTM Mar 2026 | $170.53M | +6.8% | +0.7% | 30.5% | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Jun 2026 | $39.85M | +63.8% | -10.3% | 12.8% | |
| LTM Feb 2026 | $296.57K | -66.5% | -41.2% | 0.0% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $0 | — | — | 0.0% |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding OGN) | $296.57K | +18.2% | +0.7% | 0.0% | |
Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.3B | 6.17B | 6.26B | 6.4B | 6.22B |
| Cost of Revenue | 2.38B | 2.29B | 2.52B | 2.69B | 2.85B |
| Gross Profit | 3.92B | 3.88B | 3.75B | 3.72B | 3.36B |
| Gross Margin | 62.2% | 62.8% | 59.8% | 58.0% | 54.1% |
| Research & Development | 443M | 471M | 528M | 469M | 366M |
| Selling, General & Admin | 1.67B | 1.7B | 1.89B | 1.76B | 1.71B |
| Operating Expenses | 2.01B | 2.18B | 2.42B | 2.23B | 2.09B |
| Depreciation & Amortization | 195M | 212M | 236M | 277M | 361M |
| EBITDA | 1.98B | 1.76B | 1.44B | 1.6B | 1.29B |
| EBITDA Margin | 31.4% | 28.4% | 22.9% | 25.1% | 20.8% |
| Operating Income | 1.92B | 1.71B | 1.33B | 1.49B | 1.29B |
| Operating Margin | 30.4% | 27.6% | 21.2% | 23.2% | 20.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 258M | 422M | 527M | 520M | 504M |
| Other Income / Expenses | (386M) | (583M) | (654M) | (679M) | (860M) |
| Income Before Tax | 1.53B | 1.12B | 673M | 807M | 425M |
| Pre-Tax Margin | 24.3% | 18.2% | 10.7% | 12.6% | 6.8% |
| Income Tax Expense | 178M | 205M | (350M) | (57M) | 238M |
| Net Income | 1.35B | 917M | 1.02B | 864M | 187M |
| Net Margin | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
| EPS (Basic) | 5.33 | 3.61 | 4.01 | 3.36 | 0.72 |
| EPS (Diluted) | 5.33 | 3.59 | 3.99 | 3.33 | 0.72 |
| Weighted Avg Shares | 253.55M | 254.08M | 255.24M | 257.05M | 259.5M |
| Weighted Avg Shares (Diluted) | 253.55M | 255.17M | 256.27M | 259.15M | 260.76M |
Organon & Co.
NYSE:OGN
Intrinsic Alpha fair value
Locked
Current Price
$13.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.